Transmitted human immunodeficiency virus type 1 carrying the D67N or K219Q/E mutation evolves rapidly to zidovudine resistance in vitro and shows a high replicative fitness in the presence of zidovudine

Journal of Virology
J Gerardo García-LermaW Heneine

Abstract

Drug-naive patients infected with drug-resistant human immunodeficiency virus type 1 (HIV-1) who initiate antiretroviral therapy show a shorter time to virologic failure than patients infected with wild-type (WT) viruses. Resistance-related HIV genotypes not commonly seen in treated patients, which likely result from reversion or loss of primary resistance mutations, have also been recognized in drug-naive persons. Little work has been done to characterize the patterns of mutations in these viruses and the frequency of occurrence, their association with phenotypic resistance, and their effect on fitness and evolution of resistance. Through the analysis of resistance mutations in 1082 newly diagnosed antiretroviral-naive persons from the United States, we found that 35 of 48 (72.9%) persons infected with HIV-1 containing thymidine analog mutations (TAMs) had viruses that lacked a primary mutation (T215Y/F, K70R, or Q151M). Of these viruses, 9 (25.7%) had only secondary TAMs (D67N, K219Q, M41L, or F77L), and all were found to be sensitive to zidovudine (AZT) and other drugs. To assess the impact of secondary TAMs on the evolution of AZT resistance, we generated recombinant viruses from cloned plasma-derived reverse transcriptase ...Continue Reading

References

Oct 7, 1993·The New England Journal of Medicine·P HermansN Clumeck
Apr 22, 1993·The New England Journal of Medicine·A EriceH H Balfour
Sep 1, 1995·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·J VeenstraR A Coutinho
Sep 29, 1999·JAMA : the Journal of the American Medical Association·D BodenM Markowitz
Sep 29, 1999·JAMA : the Journal of the American Medical Association·S J LittleD D Richman
Mar 18, 2000·Antimicrobial Agents and Chemotherapy·C J PetropoulosJ M Whitcomb
Nov 8, 2001·Proceedings of the National Academy of Sciences of the United States of America·J G Garcia-LermaW Heneine
Nov 22, 2001·Proceedings of the National Academy of Sciences of the United States of America·D R Kuritzkes
Apr 30, 2002·Current Opinion in Infectious Diseases·M NijhuisC Boucher
Jul 4, 2002·JAMA : the Journal of the American Medical Association·Robert M GrantJames O Kahn
Aug 9, 2002·The New England Journal of Medicine·Susan J LittleDouglas D Richman
Jun 14, 2003·AIDS Research and Human Retroviruses·Stephen TaylorDeenan Pillay
Jun 8, 2004·The Journal of Infectious Diseases·Hillard S WeinstockJonathan E Kaplan

❮ Previous
Next ❯

Citations

May 8, 1993·Biochimica Et Biophysica Acta·A GasbarriniD H Van Thiel
Feb 17, 1994·Biochimica Et Biophysica Acta·A GasbarriniA B Borle
Jun 19, 1993·Biochimica Et Biophysica Acta·H Y LiG A Quamme
Oct 16, 2007·Clinical Microbiology Reviews·Carrie Dykes, Lisa M Demeter
Sep 21, 2012·Journal of Clinical Microbiology·Astrid GallPaul Kellam
Nov 17, 2006·Journal of Virology·Peter ZimbwaRodney E Phillips
Apr 23, 2013·Current Opinion in Virology·Kalyan Das, Eddy Arnold
Feb 22, 2008·Virus Research·Javier Martinez-Picado, Miguel Angel Martínez
Sep 17, 2013·Journal of Clinical Laboratory Analysis·Sayompoo SanguansittianantPalanee Ammaranond
Nov 29, 2011·Fundamental & Clinical Pharmacology·Palanee Ammaranond, Sayompoo Sanguansittianan
Sep 29, 2015·AIDS Research and Human Retroviruses·Winfrida CheriroElijah Songok
Jun 14, 2005·The Journal of Antimicrobial Chemotherapy·J Gerardo García-Lerma
Oct 28, 2016·Journal of Acquired Immune Deficiency Syndromes : JAIDS·Alejandro PirontiUNKNOWN EuResist Network Study Group
Jan 11, 2007·The Journal of Antimicrobial Chemotherapy·Clare L BoothAnna Maria Geretti
Apr 24, 2007·The Journal of Antimicrobial Chemotherapy·Clare L Booth, Anna Maria Geretti
Jan 29, 2021·Chemical Reviews·Maria E CilentoStefan G Sarafianos
Oct 6, 2021·The Pediatric Infectious Disease Journal·Cassie WeylandMary E Paul

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Antimicrobial Resistance (ASM)

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.

Antimicrobial Resistance

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.